ReviewCancers2022
PET-CT in Clinical Adult Oncology-IV. Gynecologic and Genitourinary Malignancies.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- The role of PET/CT in preoperative decision-making for secondary cytoreduction in recurrent ovarian cancer.BMC cancer · 2026Article
- Comparative Performance ofWorld journal of nuclear medicine · 2026Article
- Normal physiological variants and benign conditions in pelvic oncologic fluorodeoxyglucose positron emission tomography/magnetic resonance imaging.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Review
- Effect of data-driven motion correction for respiratory movement on lesion detectability in PET-CT: a phantom study.EJNMMI physics · 2025Article
- Investigation of the distribution of inguinal lymph nodes and delineation of the inguinal clinical target volume usingBMC cancer · 2024Article
- Incidental endometrial cancer detected on FDG PET/CT imaging for melanoma.Radiology case reports · 2024Article
- 18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol.BJUI compass · 2023Article
- Review
- Retrospective Analysis of the Predictive Value ofDiagnostics (Basel, Switzerland) · 2023Article
- Clinical practice in prostate PET imaging.Therapeutic advances in medical oncology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concurrently acquired positron emission tomography and computed tomography (PET-CT) is an advanced imaging modality with diverse oncologic applications, including staging, therapeutic assessment, restaging and longitudinal surveillance. This series of six review articles focuses on providing practical information to providers and imaging professionals regarding the best use and interpretative strategies of PET-CT for oncologic indications in adult patients. In this fourth article of the series, the more common gynecological and adult genitourinary malignancies encountered in clinical practice are addressed, with an emphasis on Food and Drug Administration (FDA)-approved and clinically available radiopharmaceuticals. The advent of new FDA-approved radiopharmaceuticals for prostate cancer imaging has revolutionized PET-CT imaging in this important disease, and these are addressed in this report. However, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.